<DOC>
	<DOCNO>NCT01511133</DOCNO>
	<brief_summary>This study aim test clinical sample ( stool serum ) previously collect clinical development HRV vaccine , identify evidence PCV-1 replication and/or immune response PCV-1 vaccinate infant .</brief_summary>
	<brief_title>Serological Response Porcine Circovirus Type 1 ( PCV-1 ) PCV-1 DNA Stools Infants Following Administration Rotarix™</brief_title>
	<detailed_description>Serum stool sample collect 4 clinical trial previously conduct HRV vaccine ( Rotarix™ ) use study .</detailed_description>
	<mesh_term>Rotavirus Infections</mesh_term>
	<criteria>Inclusion criterion : Subjects enrol previously randomize , doubleblind placebocontrolled study 444563/022 ( NCT00263666 ) , 444563/033 ( NCT00757770 ) , 103477 ( NCT00169455 ) , 104480 ( NCT00137930 ) ; Infants age 6 12 week Dose 1 vaccinate either HRV vaccine placebo ; Infants sufficient residual volume stool sample predetermine time point available ; Infants sufficient residual volume pre post vaccination blood sample available . Exclusion criterion : Not applicable</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Laboratory evaluation</keyword>
	<keyword>infant</keyword>
	<keyword>Porcine circovirus type 1 ( PCV-1 )</keyword>
	<keyword>serologic response</keyword>
	<keyword>human rotavirus ( HRV ) vaccine</keyword>
</DOC>